Company intelligence / Profile preview

LuminUltra

Fredericton, New Brunswick, Canadaluminultra.com ↗

Ownership: Private
Development stage: Commercial

Overview

LuminUltra’s products are commercially available worldwide. The company played a key role as a supplier of COVID‑19 clinical testing reagents to the Government of Canada during the pandemic. Their platforms provide rapid results for environmental/industrial/clinical microbiological monitoring; no traditional drug development or clinical trial pipeline exists as they focus on diagnostics rather than therapeutics.

Therapeutic areas: Infectious Diseases
Modalities: Device (diagnostic testing kits)Molecular diagnostic technology (qPCR-based assays)ATP-based microbial detection technology (2nd Generation ATP®)Reagents for molecular diagnostics and environmental monitoring
Industry: Molecular Diagnostics

Partnerships

CEC Analytics (auto-sampling integration partner)

Beyond the preview

Go deeper on LuminUltra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LuminUltra.

Explore the full profile